You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Sample Processing Cartridges for Rapid PCR TB Detection

    SBC: CEPHEID            Topic: N/A

    DESCRIPTION (provided by applicant): Cepheid Inc and the New Jersey Medical School have developed an assay system that integrates sample processing and real-time PCR diagnosis into a single, hands free process. During the successful completion of a phase I STTR application we demonstrated that this system simultaneously detect the presence of Mycobacterium tuberculosis (TB) and diagnose rifampin r ...

    STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  2. HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension

    SBC: VASCULAR BIOSCIENCES, INC.            Topic: NHLBI

    PUBLIC ABSTRACT This projectin response to announcement HLSdescribes a development program for CARSKNKDCCARa synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapiesfor the treatment of pulmonary hypertensionPHPH is a disorder of elevated pulmonary vascular resistance characterized by progressive thickeni ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Pirenzepine for CIPN

    SBC: WinSanTor, Inc.            Topic: NCI

    PROJECT SUMMARY Chemotherapy induced peripheral neuropathyCIPNis a debilitating condition that afflictsof cancer patients undergoing chemotherapy and limits the dose and duration of treatmentSymptoms range from sensory loss to painful neuropathy and are accompanied by electrophysiological and structural indices of nerve damageThe American Society of Clinical Oncology currently makes no recommendat ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523

    SBC: SignalRx Pharmaceuticals Inc.            Topic: 102

    There is an unmet need to inhibit the key cancer promoting transcription factor MYCboth c MYC and MYCNthat act downstream of many cell receptors and signal transcription pathways to activate genes for cancer cell resistance and tumor growthTo datesmall molecule inhibitors of MYC have remained elusiveIn our Phase I STTRCAwe developed a lead compoundSFwhich displays potent orthogonal inhibitory acti ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Testing a male oral contraceptive targeting Eppin

    SBC: EPPIN PHARMA INC            Topic: NICHD

    The global contraceptives market was valued at $billion inand is expected to grow at a CAGR offromtoto reach an estimated value of $billion inThe contraceptive market consists of short term methods such as condoms and oral contraceptionlong term methods including implants and IUDsand permanent methods such as tubal ligations and vasectomiesEppin Pharmaandapos s product has a unique set of characte ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. The nGoggle: A portable brain-based device for assessment of visual function deficits

    SBC: NGOGGLE INC            Topic: N

    PROJECT SUMMARY Assessment of loss of visual function outside the foveal area is an essential component of the management of numerous conditionsincluding glaucomaretinal and neurological disordersDespite the significant progress achieved with the development of standard automated perimetrySAPmany decades agoassessment of visual field loss with SAP still has significant drawbacksSAP testing is limi ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells

    SBC: CELL MICROSYSTEMS INC            Topic: NIAID

    Project SummaryAdoptive cell therapyACTis an emerging immunotherapy which shows significant promise in treating both leukemia and solid tumorsas well as certain infectious diseasesACT comprises the isolation and ex vivo expansion of cytotoxic T lymphocytesCTLsrecognizing epitopes of a mutated or aberrantly expressed protein present almost exclusively on the surface of a patient s tumor cellsTo mee ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment

    SBC: BIOVINC, LLC            Topic: NIDCR

    ABSTRACT Dental implants are a central part of modern dental practice with the overall market for replacement and reconstruction of teeth expected to reach over $billion in the next several yearsIt is estimated that overmillion people in the United States are missing all of the teeth in one or both of their jaws leading to lower quality of lifeMost of these implants will be successful for long ter ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Peripheral FAAH as a target for novel analgesics

    SBC: Anteana Therapeutics Inc            Topic: NIDA

    DESCRIPTIONprovided by applicantPain management is a significant unmet medical needAnandamide is an endocannabinoid mediator that plays important roles in the regulation of painPrevious work has shown that endocannabinoid receptors located outside the central nervous systemCNSexert a powerful regulatory control over pain initiationThe biological actions of anandamide are stopped by the enzymefatty ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. A nanoparticle delivery system for CRISPR/Cas9 based therapeutics

    SBC: ATGC Inc.            Topic: 100

    Abstract Applications of customizable nucleases such as CRISPRclustered regularly interspaced short palindromic repeatsCasCRISPR associated proteinhave enabled efficient and precise gene correction in vitroand hold promises for eventually achieving in vivo gene correction therapyHoweverto apply CRISPR Casin therapeutic settingsseveral major challenges remain to be addressedihomologous recombinatio ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government